Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
about
Hsp90 Inhibitors for the Treatment of Chronic Myeloid LeukemiaA target-disease network model of second-generation BCR-ABL inhibitor action in Ph+ ALLSecondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate.Striking the target in Wnt-y conditions: intervening in Wnt signaling during cancer progressionThe PAX5 gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemia but is not associated with outcome. A report on behalf of the GIMEMA Acute Leukemia Working Party.Imatinib mesylate in the treatment of hematologic malignancies.Severe hemorrhagic colitis in a patient with chronic myeloid leukemia in the blastic phase after dasatinib use.Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease.Nilotinib: a new tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignanciesAdverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib.Tyrosine kinase inhibitors in acute and chronic leukemias.First-line treatment of chronic myeloid leukemia with nilotinib: critical evaluationImatinib, dasatinib and nilotinib: a review of adverse cutaneous reactions with emphasis on our clinical experience.Syndrome of inappropriate secretion of antidiuretic hormone associated with imatinib.Activity-based kinase profiling of approved tyrosine kinase inhibitors.Efficacy of dasatinib in conjunction with alpha-interferon for the treatment of imatinib-resistant and dasatinib-resistant Ph+ acute lymphoblastic leukemia.Integration of ruxolitinib into dose-intensified therapy targeted against a novel JAK2 F694L mutation in B-precursor acute lymphoblastic leukemia.Impact of Chromosomal Rearrangement upon DNA Methylation Patterns in Leukemia.High prevalence of BCR-ABL fusion transcripts with poor prognostic impact among adult ALL patients: report from Pakistan.
P2860
Q26771790-1C89436E-DE41-44B4-B84F-D005AAF199B2Q28534337-A1C62B8B-B805-4F03-8AE8-F0D6683C04C9Q33861815-370A62C9-5585-441B-8850-84FD2997A627Q33965278-E64F7E68-4725-4961-9A00-BC3FE7AD1D26Q34166538-5EED5837-9AF8-439C-991A-6CA90D215999Q36960525-FE0848CD-6786-463E-A55F-2A7C02C45956Q37087013-4F93F709-A4F4-4EEB-8328-E91D62F5BD6EQ37248354-F2B2C21E-CD24-4E8F-BC05-51A1C3FA9941Q37310478-E312B831-8184-4F4B-BE07-E4E534D38889Q37432231-F1133A10-49E7-4629-AC04-BC79453952CEQ37930709-55BA1D53-291D-4B29-B23E-5CB2B0DC2C16Q38004075-680F900C-219C-445C-BF3A-56B02CB09291Q38066199-9F9BFE0D-B0AD-44B4-89AC-A3CD784749C0Q38101103-783497C6-25C2-4B2C-8691-F17AF86979D9Q40404567-3A8B035E-7C84-4FCA-84A2-E9EE03C56D5AQ42713576-01E850DC-8568-4BFA-8CCE-6525A50EC37AQ46022670-BF2ADF6B-7759-4D3A-B547-CBA3E0228C12Q51319927-BD77097B-25E7-47DB-BA3F-120A2B66E13EQ52761621-A7042996-1BB5-4696-AD44-D43720DC1CFDQ54611921-35917E15-1E89-4EBC-AA20-699A6A7FAB17
P2860
Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Tyrosine kinase inhibitors for ...... acute lymphoblastic leukemia.
@en
type
label
Tyrosine kinase inhibitors for ...... acute lymphoblastic leukemia.
@en
prefLabel
Tyrosine kinase inhibitors for ...... acute lymphoblastic leukemia.
@en
P2860
P356
P1433
P1476
Tyrosine kinase inhibitors for ...... acute lymphoblastic leukemia.
@en
P2093
Pier Paolo Piccaluga
Stefania Paolini
P2860
P304
P356
10.1002/CNCR.22881
P407
P577
2007-09-01T00:00:00Z